Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019


#89301

70pages

GlobalData

$ 3995

In Stock



GlobalData, the industry analysis specialist, has released its new report, Laryngeal Cancer Therapeutics Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Laryngeal Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Laryngeal Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Laryngeal Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Laryngeal Cancer Therapeutics market. Its scope includes 

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Laryngeal Cancer Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Laryngeal Cancer Therapeutics market. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Laryngeal Cancer Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Laryngeal Cancer Therapeutics market
Reasons to buy

The report will enhance your decision making capability. It will allow you to 

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Laryngeal Cancer Therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Laryngeal Cancer Therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Laryngeal Cancer Therapeutics market landscape? Identify, understand and capitalize.
Table of Content

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Laryngeal Cancer Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Risk Factors 9
2.4 Signs and Symptoms 9
2.5 Diagnosis 10
2.6 Staging (TNM Classification) 11
2.7 Treatment 14
2.7.1 Treatment by Stage of the Disease 15
2.7.2 Surgery 16
2.7.3 Radiation Therapy 16
2.7.4 Chemotherapy 17
2.7.5 Targeted Therapy 17
2.8 GlobalData Pipeline Report Guidance 21

3 Laryngeal Cancer Therapeutics - Market Characterization 22
3.1 Laryngeal Cancer Therapeutics Market Size (2006-2011) - Global 22
3.2 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - Global 24
3.3 Laryngeal Cancer Therapeutics Market Size (2006-2011) - The US 26
3.4 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - The US 27
3.5 Laryngeal Cancer Therapeutics Market Size (2006-2011) - The UK 28
3.6 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - The UK 29
3.7 Laryngeal Cancer Therapeutics Market Size (2006-2011) - France 30
3.8 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - France 31
3.9 Laryngeal Cancer Therapeutics Market Size (2006-2011) - Germany 32
3.10 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - Germany 33
3.11 Laryngeal Cancer Therapeutics Market Size (2006-2011) - Italy 34
3.12 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - Italy 35
3.13 Laryngeal Cancer Therapeutics Market Size (2006-2011) - Spain 36
3.14 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - Spain 37
3.15 Laryngeal Cancer Therapeutics Market Size (2006-2011) - Japan 38
3.16 Laryngeal Cancer Therapeutics Market Forecast (2011-2019) - Japan 39
3.17 Drivers and Barriers for Laryngeal Cancer Therapeutic Market 40
3.17.1 Drivers for the Laryngeal Cancer Therapeutics Market 40
3.17.2 Barriers for the Laryngeal Cancer Therapeutics Market 40
3.18 Key Events Impacting the Future Market 41
3.19 Opportunity and Unmet Need 42
3.20 Key Takeaway 43

4 Laryngeal Cancer Therapeutics Market - Competitive Assessment 44
4.1 Overview 44
4.1.1 Strategic Competitor Assessment 44
4.2 Laryngeal Cancer Therapeutics - Profile for Marketed Products 45
4.2.1 Erbitux (cetuximab) 45
4.2.2 Taxotere (docetaxel) 46
4.2.3 Bleomycin 47
4.3 Key Takeaway 48

5 Laryngeal Cancer Therapeutics Market - Pipeline Assessment 49
5.1 Overview 49
5.2 Strategic Pipeline Assessment 49
5.3 Laryngeal Cancer Pipeline Analysis - Pipeline by Phases of Development 50
5.3.1 Laryngeal Cancer Therapeutics - Phase III Pipeline 50
5.3.2 Laryngeal Cancer Therapeutics - Phase II Pipeline 51
5.3.3 Laryngeal Cancer Therapeutics - Phase I/II Pipeline 51
5.3.4 Laryngeal Cancer Therapeutics - Phase I Pipeline 51
5.4 Laryngeal Cancer Pipeline by Mechanism of Action 52
5.5 Laryngeal Cancer Technology Trends Analytical Framework 53
5.6 Laryngeal Cancer Therapeutics - Profile for Late Stage Molecules 54
5.6.1 Bevacizumab 54
5.6.2 Panitumumab 54
5.6.3 S-1 55
5.7 Key Takeaway 55

6 Laryngeal Cancer Therapeutics - Clinical Trials Mapping 56
6.1 Clinical Trials Mapping by Region/Country 56
6.2 Clinical Trials Mapping by Phase 57
6.3 Clinical Trials Mapping by Trial Status 58
6.4 Clinical Trials Mapping by Overall Sponsors 59
6.5 Clinical Trial Mapping by Prominent Sponsors 60

7 Laryngeal Cancer Therapeutics - Strategic Assessment 61
7.1 Future Market Competition Scenario 61

8 Laryngeal Cancer Therapeutics - Future Players 62
8.1 Introduction 62
8.2 Company Profiles 62
8.2.1 Amgen Inc. 62

9 Global Laryngeal Cancer Therapeutics Market - Appendix 64
9.1 Definitions 64
9.2 Acronyms 64
9.3 Methodology 65
9.3.1 Coverage 66
9.3.2 Secondary Research 66
9.3.3 Forecasting 66
9.3.4 Primary Research 68
9.3.5 Expert Panel Validation 69
9.4 Contact Us 69
9.5 Disclaimer 69
9.6 Bibliography 69

Table 1: Laryngeal Cancer - Epidemiology 2010 8
Table 2: Stage Distribution and Five-year Relative Survival by Stage at Diagnosis for 2001-2007 8
Table 3: Laryngeal Cancer , TNM Definitions 11
Table 4: Laryngeal Cancer - Anatomic Stage/Prognostic Groups and Development of Cancer Cells 13
Table 5: Laryngeal Cancer Treatment Options by Stages 15
Table 6: Laryngeal Cancer - Chemotherapy with Radiation Therapy for Locally Advanced Stages (Stage III - IVB) 18
Table 7: Laryngeal Cancer - Induction Chemotherapy for Locally Advanced Stages III-IVB 18
Table 8: Laryngeal Cancer - First-Line Chemotherapy for Metastatic or Recurrent Stage IVC 19
Table 9: Laryngeal Cancer , Second and Third-Line Chemotherapy for Metastatic or Recurrent Stage (Stage IVC) 20
Table 10: Laryngeal Cancer Therapeutics, Global, Market Revenue ($m), 2006-2011 22
Table 11: Laryngeal Cancer Therapeutics, Global, Forecast ($m), 2011-2019 24
Table 12: Laryngeal Cancer Therapeutics, The US, Market Revenue ($m), 2006-2011 26
Table 13: Laryngeal Cancer Therapeutics, The US, Forecast ($m), 2011-2019 27
Table 14: Laryngeal Cancer Therapeutics, The UK, Market Revenue ($m), 2006-2011 28
Table 15: Laryngeal Cancer Therapeutics, The UK, Forecast ($m), 2011-2019 29
Table 16: Laryngeal Cancer Therapeutics, France, Market Revenue ($m), 2006-2011 30
Table 17: Laryngeal Cancer Therapeutics, France, Forecast ($m), 2011-2019 31
Table 18: Laryngeal Cancer Therapeutics, Germany, Market Revenue ($m), 2006-2011 32
Table 19: Laryngeal Cancer Therapeutics, Germany, Forecast ($m), 2011-2019 33
Table 20: Laryngeal Cancer Therapeutics, Italy, Market Revenue ($m), 2006-2011 34
Table 21: Laryngeal Cancer Therapeutics, Italy, Forecast ($m), 2011-2019 35
Table 22: Laryngeal Cancer Therapeutics, Spain, Market Revenue ($m), 2006-2011 36
Table 23: Laryngeal Cancer Therapeutics, Spain, Forecast ($m), 2011-2019 37
Table 24: Laryngeal Cancer Therapeutics, Japan, Market Revenue ($m), 2006-2011 38
Table 25: Laryngeal Cancer Therapeutics, Japan, Forecast ($m), 2011-2019 39
Table 26: Laryngeal Cancer Therapeutics - Phase III Pipeline, 2011 50
Table 27: Laryngeal Cancer Therapeutics - Phase II Pipeline, 2011 51
Table 28: Laryngeal Cancer Therapeutics - Phase I/II Pipeline, 2011 51
Table 29: Laryngeal Cancer Therapeutics - Phase I Pipeline, 2011 51
Table 30: Laryngeal Cancer Therapeutics - Clinical Mapping by Region/Country, 2011 56
Table 31: Laryngeal Cancer Therapeutics - Clinical Mapping by Phase, 2011 57
Table 32: Laryngeal Cancer Therapeutics - Clinical Mapping by Trial Status, 2011 58
Table 33: Laryngeal Cancer Therapeutics - Clinical Mapping by Overall Sponsors, 2011 59
Table 34: Laryngeal Cancer Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 60
Table 35: Amgen - Molecule in the Pipeline for Head and Neck Cancer, 2011 62
Figure 1: Laryngeal Cancer - Disease Characterization 7
Figure 2: Laryngeal Cancer Therapeutics, Global, Market Revenue ($m), 2006-2011 22
Figure 3: Laryngeal Cancer Therapeutics, Market Share ($m, %), 2011 23
Figure 4: Laryngeal Cancer Therapeutics, Global, Forecast ($m), 2011-2019 24
Figure 5: Laryngeal Cancer Therapeutics, Market Share ($m, %), 2019 25
Figure 6: Laryngeal Cancer Therapeutics, The US, Market Revenue ($m), 2006-2011 26
Figure 7: Laryngeal Cancer Therapeutics, The US, Forecast ($m), 2011-2019 27
Figure 8: Laryngeal Cancer Therapeutics, The UK, Market Revenue ($m), 2006-2011 28
Figure 9: Laryngeal Cancer Therapeutics, The UK, Forecast ($m), 2011-2019 29
Figure 10: Laryngeal Cancer Therapeutics, France, Market Revenue ($m), 2006-2011 30
Figure 11: Laryngeal Cancer Therapeutics, France, Forecast ($m), 2011-2019 31
Figure 12: Laryngeal Cancer Therapeutics, Germany, Market Revenue ($m), 2006-2011 32
Figure 13: Laryngeal Cancer Therapeutics, Germany, Forecast ($m), 2011-2019 33
Figure 14: Laryngeal Cancer Therapeutics, Italy, Market Revenue ($m), 2006-2011 34
Figure 15: Laryngeal Cancer Therapeutics, Italy, Forecast ($m), 2011-2019 35
Figure 16: Laryngeal Cancer Therapeutics, Spain, Market Revenue ($m), 2006-2011 36
Figure 17: Laryngeal Cancer Therapeutics, Spain, Forecast ($m), 2011-2019 37
Figure 18: Laryngeal Cancer Therapeutics, Japan, Market Revenue ($m), 2006-2011 38
Figure 19: Laryngeal Cancer Therapeutics, Japan, Forecast ($m), 2011-2019 39
Figure 20: Laryngeal Cancer Therapeutics, Key Events Impacting the Future Market, 2011 41
Figure 21: Opportunity and Unmet Need in the Laryngeal Cancer Therapeutics Market, 2011 42
Figure 22: Laryngeal Cancer Therapeutics, Strategic Competitor Assessment, 2011 44
Figure 23: Laryngeal Cancer Therapeutics - Pipeline by Phase of Development, 2011 50
Figure 24: Laryngeal Cancer Market - Clinical Pipeline by Mechanism of Action, 2011 52
Figure 25: Technology Trends Analytical Framework of the Laryngeal Cancer Pipeline, 2011 53
Figure 26: Technology Trends Analytical Framework of Laryngeal Cancer Pipeline - Description, 2011 53
Figure 27: Laryngeal Cancer Therapeutics - Clinical Mapping by Region/Country, 2011 56
Figure 28: Laryngeal Cancer Therapeutics - Clinical Mapping by Phase, 2011 57
Figure 29: Laryngeal Cancer Therapeutics - Clinical Mapping by Trial Status, 2011 58
Figure 30: Laryngeal Cancer Therapeutics - Clinical Mapping by Overall Sponsors, 2011 59
Figure 31: Laryngeal Cancer Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 60
Figure 32: Laryngeal Cancer Therapeutics, Strategic Assessment, 2011 61
Figure 33: GlobalData Market Forecasting Model 68